David, any thoughts from your side?

Yeah, maybe just a little bit of thank you on the longer term aspect of what you were talking about.

So yeah, that is important and can be a tricky part of our work is getting buy-in from senior leaders to have a sort of a three-year roadmap or a five-year roadmap towards success in the adoption of a new approach.

The paper goes into details about how we have to work across from invention all the way into implementation.And of course, as you were alluding to, Jurgen, there are many different ways of doing that in big pharma or CROs.

But in big pharma we might be working a little bit more from the left-hand side of that equation, if you like, but we still also have to tailor what's developed to specific project needs, which is in effect very similar to what you're doing in CROs.

So there's, there's lots of similarities there.

Maybe I could touch a little bit on the training aspect, which is a great opportunity that we have in big pharma 'cause we have such a big audience.

I wonder if you could give me, or give the audience I should say again, give the audience some idea of what's it look like to be a great methodology statistician, and what would a typical day look like?